Precision therapies and vaccines for different cancer indications

IngenOx Therapeutics is focused on addressing urgent unmet needs in oncology, particularly targeting late-stage solid tumors and relapsed or refractory lymphomas that have poor prognoses. The company is developing a multi-asset pipeline of novel therapeutic assets that utilize synergistic and complementary mechanisms, supported by robust scientific and clinical data. IngenOx aims to create precision cancer vaccines that can effectively target various tumor types, including those that are resistant to existing treatments. The company recognizes the challenges posed by immunologically "cold" tumors, which evade detection by the immune system and show limited response to conventional therapies, including checkpoint inhibitors. By developing innovative drugs and vaccines, IngenOx seeks to improve outcomes for patients suffering from these difficult-to-treat cancers.

The company's clinical pipeline includes several promising candidates, such as Zabadinostat, an immune modulator with a favorable safety profile and demonstrated efficacy in colorectal cancer, and AT-101, a proprietary small molecule inhibitor targeting Protein Arginine Methyltransferase 5 (PRMT5). Additionally, IngenOx is advancing PCV-001, the first precision cancer vaccine generated from its proprietary platform, which is currently in preclinical studies. Through a combination of in-house drug discovery capabilities and strategic collaborations, IngenOx is committed to translating scientific innovations into effective clinical treatments, with the goal of becoming a leader in cancer drug development.

United Kingdom

IngenOx Therapeutics is a clinical-stage Oxford University spinout developing innovative drugs and vaccines aimed at re-invigorating the immune response against cold tumours.

IngenOx Therapeutics

Company Details